Albert Garcia Romeu: The Case for Weight-Adjusted Psilocybin Dosing

Psilocybin therapy requires a refined approach to dosage to ensure optimal clinical outcomes and FDA approval. Studies demonstrate that flat dosing - where every participant receives the same amount - is significantly easier and less costly to implement than weight-adjusted protocols. Data from clinical trials across various populations indicate that body weight and body mass index have negligible effects on the intensity, occurrence of mystical experiences, or challenging psychological states induced by psilocybin. Consequently, a refined, universal dosing strategy may provide comparable therapeutic efficacy while decreasing logistical and financial burdens, clearing a path for larger scale Phase 3 clinical investigations.